--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-22-280241" form_type: "8-K" ticker: "SPRY" cik: "0001671858" company_name: "ARS Pharmaceuticals, Inc." filed_at: "2022-11-08T23:59:59+00:00" generated_at: "2026-06-22T03:54:12.042497+00:00" event_type: "m_and_a" sentiment: "positive" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Silverback Therapeutics merges with ARS Pharma; renamed ARS Pharmaceuticals, new board and focus on neffy ## Summary - Merger completed Nov 8, 2022; ARS Pharma becomes wholly owned subsidiary of re-named ARS Pharmaceuticals, Inc. - ARS Pharma equityholders own ~62% and prior Silverback equityholders ~38% on a fully diluted basis post-merger. - New board includes eight ARS Pharma designees; executives: Richard Lowenthal (CEO), Kathleen Scott (CFO), Sarina Tanimoto (CMO), Eric Karas (CCO), Justin Chakma (CBO/Secretary). - Company now focusing on neffy (intranasal epinephrine) for Type I allergic reactions and anaphylaxis. - Stock symbol changes from SBTX to SPRY, effective Nov 9, 2022, on Nasdaq. ## SEC filing metadata - accession: 0001193125-22-280241 - form_type: 8-K - ticker: SPRY - cik: 0001671858 - company_name: ARS Pharmaceuticals, Inc. - filed_at: 2022-11-08T23:59:59+00:00 - event_type: m_and_a - sentiment: positive - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 2.01, 1.01, 5.07, 3.02, 5.01, 5.02, 5.03, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/d388226d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-22-280241 - JSON: https://secwatch.observer/filing/0001193125-22-280241.json - Plain text: https://secwatch.observer/filing/0001193125-22-280241.txt ## Key facts - Executive change Maria Koehler resigned as Director at ARS Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Andrew Powell resigned as Director at ARS Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Vicki L. Capps resigned as Director at ARS Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Rajeev Dadoo was appointed as Class I Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Class I Director source text: Rajeev Dadoo, Ph.D. 52 Class I Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Sarina Tanimoto was appointed as Chief Medical Officer at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Chief Medical Officer source text: Sarina Tanimoto, M.D., M.B.A. 54 Chief Medical Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Brenton L. Saunders was appointed as Class II Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Class II Director source text: Brenton L. Saunders 52 Class II Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Peter Kolchinsky was appointed as Class II Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Class II Director source text: Peter Kolchinsky, Ph.D. 46 Class II Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Pratik Shah was appointed as Chair of the Board and Class I Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Chair of the Board and Class I Director source text: Pratik Shah, Ph.D. 52 Chair of the Board and Class I Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Russ Hawkinson was terminated as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc.. - Action: terminated - Role: Interim Chief Financial Officer source text: each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force. evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Justin Chakma was appointed as Chief Business Officer and Secretary at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Chief Business Officer and Secretary source text: Justin Chakma 33 Chief Business Officer and Secretary evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Robert Hershberg resigned as Director at ARS Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Eric Karas was appointed as Chief Commercial Officer at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Chief Commercial Officer source text: Eric Karas 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Phillip Schneider was appointed as Class III Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Class III Director source text: Phillip Schneider 66 Class III Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Jeffrey Pepe was terminated as Interim Chief Executive Officer, General Counsel and Corporate Secretary at ARS Pharmaceuticals, Inc.. - Action: terminated - Role: Interim Chief Executive Officer, General Counsel and Corporate Secretary source text: each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force. evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Jonathan S. Leff was appointed as Class III Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Class III Director source text: Jonathan S. Leff 53 Class III Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Richard Lowenthal was appointed as President and Chief Executive Officer at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: President and Chief Executive Officer source text: Richard Lowenthal, M.S., MSEL 56 President, Chief Executive Officer and Class II Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Kathleen Scott was appointed as Chief Financial Officer at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Chief Financial Officer source text: Kathleen Scott 53 Chief Financial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Jonathan Root resigned as Director at ARS Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Michael Kelly was appointed as Class I Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Class I Director source text: Michael Kelly 57 Class I Director evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Executive change Richard Lowenthal was appointed as Class II Director at ARS Pharmaceuticals, Inc.. - Action: appointed - Role: Class II Director source text: Pursuant to the terms of the Merger Agreement, each of (i) Mr. Lowenthal, Dr. Shah, Dr. Dadoo, Mr. Kelly, Dr. Kolchinsky, Mr. Leff, Mr. Saunders and Mr. Schneider were appointed to the board of directors of the Company as designees of ARS Pharma evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - Governance Changes ARS Pharmaceuticals, Inc.: Silverback Therapeutics, Inc. changed its name to ARS Pharmaceuticals, Inc. via a charter amendment effective upon merger consummation (effective 2022-11-08). - Change: charter amendment - Effective: 2022-11-08 source text: on November 8, 2022, Silverback filed the Charter Amendment changing its name from "Silverback Therapeutics, Inc." to "ARS Pharmaceuticals, Inc." evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm - M&A Transactions ARS Pharmaceuticals, Inc. underwent a change of control involving ARS Pharmaceuticals, Inc. (closed 2022-11-08). - Action: change of control - Counterparty: ARS Pharmaceuticals, Inc. - Closing: 2022-11-08 source text: On November 8, 2022, Silverback, Merger Sub and ARS Pharma consummated the transactions contemplated by the Merger Agreement evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.